For these reasons, to date, the treatment algorithm for mCRC patients in the first-line setting is based on the primary tumor location: chemotherapy plus anti-EGFR regimen is recommended for left-sided MSS, RAS and BRAF wild-type tumors, while chemotherapy plus anti-VEGF (bevacizumab) is recommended for right-sided MSS mCRC patients [46]. Here, BRAF is linked to neoplasm.